-
公开(公告)号:EP3190125A1
公开(公告)日:2017-07-12
申请号:EP17151348.4
申请日:2006-08-29
IPC分类号: C07K16/24 , C12N15/13 , A61K39/395 , A61P35/00 , A61P37/00
CPC分类号: C07K16/244 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要: Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
摘要翻译: 提供了针对人IL-23p19的工程抗体及其用途,例如人IL-23p19。 用于治疗炎症,自身免疫和增殖性疾病。
-
公开(公告)号:EP2358716B1
公开(公告)日:2016-01-06
申请号:EP09752650.3
申请日:2009-11-10
发明人: SHIPPS, JR., Gerald, W. , CHENG, Cliff, C. , HUANG, Xiaohua , ACHAB, Abdelghani, Abe , ORTH, Peter , VOIGT, Johannes, H. , SOUCY, Kyle, Ann
IPC分类号: C07D487/04 , C07D519/00 , A61P3/00 , A61K31/519
CPC分类号: C07D487/04 , C07D519/00
-
公开(公告)号:EP2485735B1
公开(公告)日:2015-07-29
申请号:EP10822452.8
申请日:2010-10-01
发明人: SHIPPS, Gerald, W., Jr. , CHENG, Clifford, C. , HUANG, Xioahua , ACHAB, Abdelghani , ORTH, Peter , VOIGT, Johannes, H.
IPC分类号: A61K31/54
CPC分类号: A61K31/54 , A61K45/06 , A61K2300/00
-
公开(公告)号:EP2866833B1
公开(公告)日:2019-05-15
申请号:EP13808570.9
申请日:2013-06-25
发明人: REICHERT, Paul , PROSISE, Winifred, W. , ORTH, Peter , NARASIMHAN, Chakravarthy , KASHI, Ramesh, S.
IPC分类号: A61K39/395 , C07K16/24
-
公开(公告)号:EP1931710B1
公开(公告)日:2017-01-18
申请号:EP06802592.3
申请日:2006-08-29
IPC分类号: C07K16/24 , C12N15/13 , A61K39/395 , A61P35/00 , A61P37/00
CPC分类号: C07K16/244 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
-
公开(公告)号:EP1976849B1
公开(公告)日:2016-03-09
申请号:EP07709799.6
申请日:2007-01-16
发明人: YU, Wensheng , TONG, Ling , CHEN, Lei , KOZLOWSKI, Joseph, A. , LAVEY, Brian, J. , SHIH, Neng-Yang , MADISON, Vincent, S. , ZHOU, Guowei , ORTH, Peter , GUO, Zhuyan , WONG, Michael, K.C. , YANG, De-Yi , KIM, Seong-Heon , SHANKAR, Bandarpalle, B. , SIDDIQUI, M., Arshad , ROSNER, Kristin, E. , DAI, Chaoyang , POPOVICI-MULLER, Janeta , GIRIJAVALLABHAN, Vinay, M. , LI, Dansu , RIZVI, Razia , MICULA, Aneta, S , FELTZ, Robert Schering-Plough Corporation
IPC分类号: C07D401/14 , C07D403/06 , A61P35/00 , A61K31/4166 , C07D471/04 , C07D473/34 , C07D473/00 , C07D491/04 , C07D495/04 , C07D417/14 , C07D413/14 , C07D405/14 , C07D403/14
CPC分类号: C07D403/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D473/00 , C07D473/34 , C07D487/04 , C07D491/04 , C07D495/04
-
公开(公告)号:EP2866833A2
公开(公告)日:2015-05-06
申请号:EP13808570.9
申请日:2013-06-25
发明人: REICHERT, Paul , PROSISE, Winifred, W. , ORTH, Peter , NARASIMHAN, Chakravarthy , KASHI, Ramesh, S.
IPC分类号: A61K39/395
CPC分类号: C07K16/244 , A61K39/39591 , C07K2299/00 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要: Crystalline forms of antibodies to human IL-23, such as antibodies to human IL-23p19 , are provided, as well as methods of producing such crystalline forms, and uses of such crystalline forms, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. In various embodiments, the anti-hulL-23 antibody crystals, such as anti-hulL-23p19 antibody crystals of the present invention are obtainable by batch crystallization methods, vapor diffusion methods, liquid-liquid diffusion methods, and dialysis. In other aspects, the invention relates to suspensions of the crystalline anti-hulL-23 antibodies of the present invention, including those at higher concentrations and lower viscosities than would be possible with a corresponding non-crystalline solution at the same concentration of antibody. In other embodiments, the anti-huiL-23 antibody crystals of the present invention have increased stability, i.e. they maintain biological activity of the anti-huiL-23 antibody, such as anti-huiL-23p 19 antibody, longer than corresponding solution formulations.
-
公开(公告)号:EP2485735A1
公开(公告)日:2012-08-15
申请号:EP10822452.8
申请日:2010-10-01
发明人: SHIPPS, Gerald, W., Jr. , CHENG, Clifford, C. , HUANG, Xioahua , ACHAB, Abdelghani , ORTH, Peter , VOIGT, Johannes, H.
IPC分类号: A61K31/54
CPC分类号: A61K31/54 , A61K45/06 , A61K2300/00
摘要: The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein (FABP) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the present invention is shown below:
-
-
-
-
-
-
-